Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Importance Breast cancer will be diagnosed in 12% of women in the United States over the
course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed …

Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …

The purpose of the American Cancer Society/American Society of Clinical Oncology Breast
Cancer Survivorship Care Guideline is to provide recommendations to assist primary care …

The 18th St Gallen International Breast Cancer Conference held in March 2023, in Vienna,
Austria, assessed significant new findings for local and systemic therapies for early breast …

Background Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared
with tamoxifen, in postmenopausal women with hormone-receptor–positive breast cancer …

Summary Background The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was
designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg) …

PURPOSE CDK4/6 inhibitors are used to treat estrogen receptor (ER)–positive metastatic
breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized …

Purpose To develop evidence-based guidelines, based on a systematic review, for
endocrine therapy for postmenopausal women with hormone receptor–positive breast …

Purpose To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs)
compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of …